PepGen (PEPG) Competitors

PepGen logo
$3.83 -0.05 (-1.29%)
Closing price 04:00 PM Eastern
Extended Trading
$3.85 +0.02 (+0.52%)
As of 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PEPG vs. NKTR, OMER, ALVO, SLN, and INBX

Should you buy PepGen stock or one of its competitors? PepGen's main competitors and comparable companies include Nektar Therapeutics (NKTR), Omeros (OMER), Alvotech (ALVO), Silence Therapeutics (SLN), and Inhibrx Biosciences (INBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PepGen compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

PepGen has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -339.67%. Nektar Therapeutics' return on equity of -29.31% beat PepGen's return on equity.

Company Net Margins Return on Equity Return on Assets
Nektar Therapeutics-339.67% -29.31% -22.32%
PepGen N/A -58.18%-48.92%

In the previous week, PepGen had 1 more articles in the media than Nektar Therapeutics. MarketBeat recorded 20 mentions for PepGen and 19 mentions for Nektar Therapeutics. PepGen's average media sentiment score of 0.39 beat Nektar Therapeutics' score of 0.22 indicating that PepGen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nektar Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
13 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
PepGen
5 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

PepGen has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$55.23M22.25-$164.08M-$6.46N/A
PepGenN/AN/A-$89.65M-$1.07N/A

Nektar Therapeutics presently has a consensus price target of $130.33, suggesting a potential upside of 262.94%. PepGen has a consensus price target of $11.40, suggesting a potential upside of 193.81%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Nektar Therapeutics is more favorable than PepGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nektar Therapeutics
1 Sell rating(s)
4 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.69
PepGen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Nektar Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, PepGen has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by insiders. Comparatively, 1.3% of PepGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Nektar Therapeutics beats PepGen on 9 of the 16 factors compared between the two stocks.

How does PepGen compare to Omeros?

PepGen (NASDAQ:PEPG) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

PepGen presently has a consensus price target of $11.40, indicating a potential upside of 193.81%. Omeros has a consensus price target of $30.33, indicating a potential upside of 117.91%. Given PepGen's higher probable upside, equities analysts clearly believe PepGen is more favorable than Omeros.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PepGen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

58.0% of PepGen shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PepGen has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, Omeros has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market.

PepGen is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PepGenN/AN/A-$89.65M-$1.07N/A
OmerosN/AN/A-$3.35M$1.2810.88

In the previous week, Omeros had 3 more articles in the media than PepGen. MarketBeat recorded 23 mentions for Omeros and 20 mentions for PepGen. PepGen's average media sentiment score of 0.39 beat Omeros' score of 0.34 indicating that PepGen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PepGen
5 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Omeros
1 Very Positive mention(s)
5 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Neutral

PepGen's return on equity of -58.18% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
PepGenN/A -58.18% -48.92%
Omeros N/A -261.02%68.52%

Summary

Omeros beats PepGen on 8 of the 13 factors compared between the two stocks.

How does PepGen compare to Alvotech?

PepGen (NASDAQ:PEPG) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Alvotech has higher revenue and earnings than PepGen. Alvotech is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PepGenN/AN/A-$89.65M-$1.07N/A
Alvotech$588.90M2.24$27.92M-$0.82N/A

PepGen has a net margin of 0.00% compared to Alvotech's net margin of -50.62%. Alvotech's return on equity of 0.00% beat PepGen's return on equity.

Company Net Margins Return on Equity Return on Assets
PepGenN/A -58.18% -48.92%
Alvotech -50.62%N/A -11.71%

58.0% of PepGen shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PepGen has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

PepGen presently has a consensus price target of $11.40, indicating a potential upside of 193.81%. Alvotech has a consensus price target of $8.40, indicating a potential upside of 92.22%. Given PepGen's stronger consensus rating and higher possible upside, equities research analysts plainly believe PepGen is more favorable than Alvotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PepGen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Alvotech
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.43

In the previous week, Alvotech had 3 more articles in the media than PepGen. MarketBeat recorded 23 mentions for Alvotech and 20 mentions for PepGen. PepGen's average media sentiment score of 0.39 beat Alvotech's score of 0.19 indicating that PepGen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PepGen
5 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alvotech
5 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

PepGen beats Alvotech on 8 of the 14 factors compared between the two stocks.

How does PepGen compare to Silence Therapeutics?

PepGen (NASDAQ:PEPG) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Silence Therapeutics has higher revenue and earnings than PepGen. Silence Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PepGenN/AN/A-$89.65M-$1.07N/A
Silence Therapeutics$560K2,197.45-$88.61M-$1.07N/A

PepGen has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. PepGen's return on equity of -58.18% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PepGenN/A -58.18% -48.92%
Silence Therapeutics -8,943.86%-102.72%-43.70%

In the previous week, PepGen had 15 more articles in the media than Silence Therapeutics. MarketBeat recorded 20 mentions for PepGen and 5 mentions for Silence Therapeutics. PepGen's average media sentiment score of 0.39 beat Silence Therapeutics' score of 0.05 indicating that PepGen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PepGen
5 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Silence Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

PepGen has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

PepGen presently has a consensus target price of $11.40, suggesting a potential upside of 193.81%. Silence Therapeutics has a consensus target price of $24.00, suggesting a potential upside of 21.21%. Given PepGen's stronger consensus rating and higher possible upside, equities analysts clearly believe PepGen is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PepGen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Silence Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

58.0% of PepGen shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

PepGen beats Silence Therapeutics on 9 of the 14 factors compared between the two stocks.

How does PepGen compare to Inhibrx Biosciences?

PepGen (NASDAQ:PEPG) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

PepGen has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 4.03, suggesting that its share price is 303% more volatile than the broader market.

PepGen presently has a consensus target price of $11.40, indicating a potential upside of 193.81%. Inhibrx Biosciences has a consensus target price of $185.00, indicating a potential upside of 149.39%. Given PepGen's stronger consensus rating and higher possible upside, research analysts plainly believe PepGen is more favorable than Inhibrx Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PepGen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Inhibrx Biosciences
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50

PepGen's return on equity of -58.18% beat Inhibrx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
PepGenN/A -58.18% -48.92%
Inhibrx Biosciences N/A -563.90%-80.38%

PepGen has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PepGenN/AN/A-$89.65M-$1.07N/A
Inhibrx Biosciences$1.30M842.80-$140.05M-$9.06N/A

58.0% of PepGen shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, PepGen had 10 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 20 mentions for PepGen and 10 mentions for Inhibrx Biosciences. PepGen's average media sentiment score of 0.39 beat Inhibrx Biosciences' score of -0.18 indicating that PepGen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PepGen
5 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inhibrx Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

PepGen beats Inhibrx Biosciences on 9 of the 14 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PEPG vs. The Competition

MetricPepGenBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$265.27M$3.97B$7.60B$11.72B
Dividend YieldN/A3.63%2.47%4.48%
P/E Ratio-3.5824.6233.5830.13
Price / SalesN/A15.438.255.59
Price / CashN/A22.9521.0121.90
Price / Book2.574.164.443.72
Net Income-$89.65M-$24.10M$3.50B$393.88M
7 Day Performance-27.19%-8.44%-6.53%-6.07%
1 Month Performance47.31%-6.54%-4.93%-7.38%
1 Year Performance-33.28%-6.71%-1.73%-7.48%

PepGen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PEPG
PepGen
3.6905 of 5 stars
$3.83
-1.3%
$11.40
+197.7%
-27.5%$265.27MN/AN/A53
NKTR
Nektar Therapeutics
2.641 of 5 stars
$37.56
+0.8%
$130.67
+247.9%
-39.7%$1.28B$55.23MN/A63
OMER
Omeros
3.1862 of 5 stars
$17.64
-1.9%
$30.33
+71.9%
+53.3%$1.28BN/A13.79175
ALVO
Alvotech
3.7976 of 5 stars
$4.21
-10.0%
$8.40
+99.8%
-15.0%$1.27B$588.90MN/A1,460
SLN
Silence Therapeutics
2.7719 of 5 stars
$19.84
+0.2%
$24.00
+21.0%
+195.5%$1.23B$560KN/A88

Related Companies and Tools


This page (NASDAQ:PEPG) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners